{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:57:16Z","timestamp":1794851836220,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"uniQure","award":["2-061-003 - Haemophilia B - Late development"],"award-info":[{"award-number":["2-061-003 - Haemophilia B - Late development"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gene therapy has the potential to offer people with haemophilia (PwH) a life free from bleeding and the burden posed by current treatment regimens. To date, gene therapy has only been available in clinical trial settings, to PwH without pre-existing or historical factor inhibitors, significant concomitant liver damage or pre-existing neutralising antibodies to the adeno-associated viruses used to deliver the therapy. Thus, most PwH treated at centres not currently involved in gene therapy trials, either as a referral\/follow-up centre or as a dosing centre, have been unable to access the therapy. This Exigency sub-study aims to gain a greater understanding of the opinions of PwH in the United Kingdom who have not had access to gene therapy: asking what they understand, what concerns they have, and whether they perceive any barriers preventing their access to gene therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-three PwH were approached; 14 consented, and one withdrew prior to interview. The mean age of the participants was 35.7\u00a0years (range 25\u201374\u00a0years). Eleven had haemophilia A and two haemophilia B. Two were treated with standard half-life factor products, five with extended half-life products, five with a FVIII mimetic and one with a clinical trial product. One family member (a participant's partner) was also interviewed. The participants identified four barriers to gene therapy: concerns about the process of gene therapy (Expectations), uncertainty about the results (outcomes), (Access) to treatment, and a lack of understanding about gene therapy (education).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This Exigency study subgroup sees gene therapy as a positive treatment development that promises an improved quality of life. For this participant group, four issues impact their decision to undergo gene therapy. If the promise of gene therapy is to be realised, these barriers need to be acknowledged and addressed by healthcare professionals, patient organisations, and gene therapy providers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03068-2","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T17:02:08Z","timestamp":1707584528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Barriers to gene therapy, understanding the concerns people with haemophilia have: an exigency sub-study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-6176","authenticated-orcid":false,"given":"Simon","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-0606","authenticated-orcid":false,"given":"Kathryn","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-4100","authenticated-orcid":false,"given":"Michael","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-5958","authenticated-orcid":false,"given":"Kate","family":"Khair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"3068_CR1","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O\u2019Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CYC, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. Adenovirus-associated virus vector-mediated gene transfer in haemophilia B. N Engl J Med. 2011;365:2357\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1108046.","journal-title":"N Engl J Med."},{"issue":"23","key":"3068_CR2","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CEM, Ragni V, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Haemophilia gene therapy with a high specific-activity factor XI variant. N Engl J Med. 2017;377(23):2215\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1708538.","journal-title":"N Engl J Med."},{"key":"3068_CR3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","volume":"385","author":"LA George","year":"2021","unstructured":"George LA, Monahan PE, Eyster ME, Sullivan SK, Ragni MV, Croteau SE, Rasko JEJ, Recht M, Samelson-Jones BJ, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape KZ, Anguela XM, High KA. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med. 2021;385:1961\u201373. https:\/\/doi.org\/10.1056\/NEJMoa2104205.","journal-title":"N Engl J Med"},{"key":"3068_CR4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY, Pasi KJ. AAV5\u2013factor VIII gene transfer in severe haemophilia A. N Engl J Med. 2017;377:2519\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1708483.","journal-title":"N Engl J Med"},{"key":"3068_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","volume":"33","author":"GQ Perin","year":"2018","unstructured":"Perin GQ, Herzog RW, Markusic DM. Update of clinical gene therapy for haemophilia. Blood. 2018;33:407\u201314. https:\/\/doi.org\/10.1182\/blood-2018-07-820720.","journal-title":"Blood."},{"key":"3068_CR6","unstructured":"European Medicines Agency. First gene therapy to treat severe haemophilia A. 24 June 2022. Accessed 9th Mar 2023. Available from: https:\/\/www.ema.europa.eu\/en\/news\/first-gene-therapy-treat-severe-haemophilia#:~:text=Roctavian%20is%20the%20first%20gene,not%20cause%20disease%20in%20humans."},{"key":"3068_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/d41586-022-04327-7","volume":"612","author":"M Naddaf","year":"2022","unstructured":"Naddaf M. Researchers welcome $3.5-million haemophilia gene therapy\u2014but questions remain. Nature. 2022;612:388\u20139. https:\/\/doi.org\/10.1038\/d41586-022-04327-7.","journal-title":"Nature."},{"key":"3068_CR8","unstructured":"McName A. Pfizer takes on haemophilia B gene therapy market with new FDA application Fidanacogene elaparvovec could be a strong contender against CSL\u2019s Hemgenix gene therapy. Pharmaceutical Technology [internet] June 27, 2023Accessed 4th September 2023. Available from www.Pharmaceutical-technology.com\/news\/pfizer-haemophilia-b-gene-therapy-fda-application\/#:~:text=Pfizer%20has%20announced%20that%20the,(MAA)%20currently%20under%20review"},{"key":"3068_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/hae.14420","volume":"27","author":"W Miesbach","year":"2021","unstructured":"Miesbach W, Chowdary P, Coppens M, Hart DP, Jimenez-Yuste V, Klamroth R, Makris M, Noone D, Peyvandi F. Delivery of AAV-based gene therapy through haemophilia centres\u2014a need for re-evaluation of infrastructure and comprehensive care: a Joint publication of EAHAD and EHC. Haemophilia. 2021;27:967\u201373. https:\/\/doi.org\/10.1111\/hae.14420.","journal-title":"Haemophilia"},{"key":"3068_CR10","unstructured":"Srivastava S. Cell and gene therapy is transforming healthcare. Part 2. Cell & Gene; 2020. Accessed 15th April 2023. Available from: https:\/\/www.cellandgene.com\/doc\/part-cell-and-gene-therapy-istransforming-healthcare-0001."},{"key":"3068_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/PPA.S239810","volume":"14","author":"W Meisbach","year":"2020","unstructured":"Meisbach W, Klamroth R. The patient experience of gene therapy for haemophilia: qualitative interviews with trial patients. Patient Prefer Adherence. 2020;14:767\u201370. https:\/\/doi.org\/10.2147\/PPA.S239810.","journal-title":"Patient Prefer Adherence"},{"key":"3068_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.17225\/jhp00174","volume":"8","author":"E Aradom","year":"2021","unstructured":"Aradom E, Gomez K. The patient gene therapy journey: Findings from qualitative interviews with trial participants at one UK Haemophilia centre. Journal of Haemophilia Practice. 2021;8:32\u201344. https:\/\/doi.org\/10.17225\/jhp00174.","journal-title":"Journal of Haemophilia Practice."},{"key":"3068_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13023-022-02256-2","volume":"17","author":"S Fletcher","year":"2022","unstructured":"Fletcher S, Jenner K, Pembroke L, Holland M, Khair K. The experiences of people with haemophilia, and their families, of gene therapy in a clinical trial setting: regaining control, the Exigency study. Orphanet J Rare Dis. 2022;17:155. https:\/\/doi.org\/10.1186\/s13023-022-02256-2.","journal-title":"Orphanet J Rare Dis"},{"key":"3068_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14774","author":"S Fletcher","year":"2023","unstructured":"Fletcher S, Jenner K, Holland M, Khair K. Expectation and loss when gene therapy for haemophilia is not an option: an exigency sub-study. Haemophilia. 2023. https:\/\/doi.org\/10.1111\/hae.14774.","journal-title":"Haemophilia"},{"key":"3068_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/hae.14190","volume":"27","author":"E van Overbeeke","year":"2020","unstructured":"van Overbeeke E, Hauber B, Michelsen S, Peerlinck K, Lambert C, Hermans C, Le PQ, Goldman M, Simoens S, Huys I. Patient perspectives regarding gene therapy in haemophilia: interviews from the PAVING study. Haemophilia. 2020;27:129\u201336. https:\/\/doi.org\/10.1111\/hae.14190.","journal-title":"Haemophilia"},{"key":"3068_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/hae.14378","volume":"1","author":"S Fletcher","year":"2021","unstructured":"Fletcher S, Jenner K, Holland M, Chaplin S, Khair K. An exploration of why men with severe haemophilia might not want gene therapy: The exigency study. Haemophilia. 2021;1:9. https:\/\/doi.org\/10.1111\/hae.14378.","journal-title":"Haemophilia."},{"key":"3068_CR17","doi-asserted-by":"publisher","first-page":"e060351","DOI":"10.1136\/bmjopen-2021-060351","volume":"12","author":"S Fletcher","year":"2022","unstructured":"Fletcher S, Pembroke L, Holland M, Khair K. Exploration of the impact of gene therapy on the lives of people with haemophilia and their families: a protocol for the mixed-methods exigency study. BMJ Open. 2022;12:e060351. https:\/\/doi.org\/10.1136\/bmjopen-2021-060351.","journal-title":"BMJ Open"},{"issue":"5","key":"3068_CR18","doi-asserted-by":"publisher","first-page":"e0232076","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS ONE. 2020;15(5):e0232076. https:\/\/doi.org\/10.1371\/journal.pone.0232076.","journal-title":"PLoS ONE"},{"issue":"23","key":"3068_CR19","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1708538.","journal-title":"N Engl J Med"},{"key":"3068_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O\u2019Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJC, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388:706\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2211644.","journal-title":"N Engl J Med."},{"key":"3068_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s13337-020-00590-2","volume":"31","author":"S Akhter","year":"2020","unstructured":"Akhter S, Akhtar S. Emerging corona virus diseases and future perspectives. VirusDis. 2020;31:113\u201320. https:\/\/doi.org\/10.1007\/s13337-020-00590-2.","journal-title":"VirusDis"},{"key":"3068_CR22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s13337-021-00715-1","volume":"32","author":"BB Basnet","year":"2021","unstructured":"Basnet BB, Basnet R, Panday R. Prospects for controlling future pandemics of SARS in highlights of SARS-CoV2. VirusDis. 2021;32:770\u20133. https:\/\/doi.org\/10.1007\/s13337-021-00715-1.","journal-title":"VirusDis."},{"key":"3068_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","volume":"132","author":"AC Nathwani","year":"2018","unstructured":"Nathwani AC, Tuddenham E, Chowdary P, McIntosh J, Lee D, Rosales C, Phillips M, Pie J, Junfang Z, Meagher MM, Reiss U, Davidoff AM, Morton CL, Riddell A. GO-8: preliminary results of a phase I\/II dose escalation trial of gene therapy for haemophilia a using a novel human factor VIII variant. Blood. 2018;132:489. https:\/\/doi.org\/10.1182\/blood-2018-99-118256.","journal-title":"Blood"},{"key":"3068_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1182\/blood-2018-99-118050","volume":"132","author":"P Chowdary","year":"2018","unstructured":"Chowdary P, Shapiro S, Davidoff AM, Reiss U, Alade R, Brooks G, Dane A, McIntosh J, Short G, Tuddenham E. A single intravenous infusion of FLT180a results in factor IX activity levels of more than 40% and has the potential to provide a functional cure for patients with haemophilia B. Blood. 2018;132:631. https:\/\/doi.org\/10.1182\/blood-2018-99-118050.","journal-title":"Blood"},{"key":"3068_CR25","doi-asserted-by":"publisher","unstructured":"Mahlangu J, Dolan G, Dougall A, Goddard NJ, Hernandez EDP, Ragni MV, Rayner B, Windyga J, Pierce GF, Srivastava A. Chapter 7: Treatment of specific hemorrhages. In: A Srivastava, E Santagostino, A Dougall, S Kitchen, M Sutherland, SW Pipe, M Carcao, et al on behalf of the WFH Guidelines for the Management of Hemophilia panellists and co-authors. WFH Guidelines for the Management of Hemophilia. Haemophilia. 2020:26(Suppl 6): 85\u201394. https:\/\/doi.org\/10.1111\/hae.14046","DOI":"10.1111\/hae.14046"},{"issue":"1","key":"3068_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2478\/jhp-2022-0021","volume":"9","author":"D Noone","year":"2022","unstructured":"Noone D, Astermark J, O\u2019Mahony B, Peyvandi F, Khair K, Pembroke L, Jenner K. The journey of gene therapy in haemophlia. Putting the patient at the centre of the hub and spoke model. J Haem Pract. 2022;9(1):156\u201366. https:\/\/doi.org\/10.2478\/jhp-2022-0021.","journal-title":"J Haem Pract"},{"issue":"5","key":"3068_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0277-9536(96)00221-3","volume":"44","author":"C Charles","year":"1997","unstructured":"Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: What does it mean? (Or it takes at least two to Tango). Soc Sci Med. 1997;44(5):681\u201392. https:\/\/doi.org\/10.1016\/S0277-9536(96)00221-3.","journal-title":"Soc Sci Med"},{"key":"3068_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12913-019-4649-1","volume":"20","author":"T Waldron","year":"2020","unstructured":"Waldron T, Carr T, McMullen L, et al. Development of a program theory for shared decision-making: a realist synthesis. BMC Health Serv Res. 2020;20:59. https:\/\/doi.org\/10.1186\/s12913-019-4649-1.","journal-title":"BMC Health Serv Res."},{"issue":"6","key":"3068_CR29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/hae.12495","volume":"20","author":"A Athale","year":"2014","unstructured":"Athale A, Giguere A, Barbara A, Krassova S, Iorio A. Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes for clinicians and patient decision aids for patients. Haemophilia. 2014;20(6):800\u20136. https:\/\/doi.org\/10.1111\/hae.12495.","journal-title":"Haemophilia"},{"issue":"1","key":"3068_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10728-008-0108-6","volume":"18","author":"L Sandman","year":"2010","unstructured":"Sandman L, Munthe C. Shared decision making, paternalism and patient choice. Health Care Anal. 2010;18(1):60\u201384. https:\/\/doi.org\/10.1007\/s10728-008-0108-6.","journal-title":"Health Care Anal"},{"key":"3068_CR31","doi-asserted-by":"publisher","first-page":"e031763","DOI":"10.1136\/bmj.open-2019-031763","volume":"9","author":"H Bomhof-Roordink","year":"2019","unstructured":"Bomhof-Roordink H, G\u00e4rtner FR, Stiggelbout AM, Pieterse AR. Key components of shared decision making models: a systematic review. BMJ Open. 2019;9:e031763. https:\/\/doi.org\/10.1136\/bmj.open-2019-031763.","journal-title":"BMJ Open"},{"issue":"1","key":"3068_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.17225\/jhp\/00178","volume":"8","author":"LA Valentino","year":"2021","unstructured":"Valentino LA, Blanchette V, Negrier C, O\u2019Mahoney B, Vias V, Sannie T, Skinner M. Personalising haemophilia management with shared decision making. J Haem Pract. 2021;8(1):69\u201379. https:\/\/doi.org\/10.17225\/jhp\/00178.","journal-title":"J Haem Pract"},{"issue":"2","key":"3068_CR33","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/hae.14214","volume":"27","author":"L Woollard","year":"2021","unstructured":"Woollard L, Gorman R, Rosenfelt DJ. Addressing patient education priorities in the era of gene therapy for haemophilia: towards evidence-informed shared decision-making. Haemophilia. 2021;27(2):e302\u20134. https:\/\/doi.org\/10.1111\/hae.14214.","journal-title":"Haemophilia"},{"key":"3068_CR34","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.2147\/PPA.S355627","volume":"16","author":"M Wang","year":"2022","unstructured":"Wang M, Negrier C, Driessler F, Goodman C, Skinner MW. The hemophilia gene therapy patient journey: questions and answers for shared decision-making. Patient Prefer Adherence. 2022;16:1439\u201347. https:\/\/doi.org\/10.2147\/PPA.S355627.","journal-title":"Patient Prefer Adherence"},{"key":"3068_CR35","doi-asserted-by":"publisher","first-page":"100890","DOI":"10.1016\/j.blre.2021.100890","volume":"52","author":"C Hermans","year":"2022","unstructured":"Hermans C, Noone D, Benson G, et al. Hemophilia treatment in 2021: Choosing the \u201coptimal\u201d treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. Blood Rev. 2022;52:100890. https:\/\/doi.org\/10.1016\/j.blre.2021.100890.","journal-title":"Blood Rev"},{"key":"3068_CR36","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1176\/appi.ps.201400307","volume":"65","author":"J Hamann","year":"2014","unstructured":"Hamann J, Heres S. Adapting shared decision making for individuals with severe mental illness. Psychiatr Serv. 2014;65:1483\u20136. https:\/\/doi.org\/10.1176\/appi.ps.201400307.","journal-title":"Psychiatr Serv"},{"key":"3068_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/virtualmentor.2012.14.7.oped2-1207","volume":"4","author":"BC Drolet","year":"2012","unstructured":"Drolet BC, White CL. Selective paternalism. AMA J Ethics. 2012;4:582\u20138. https:\/\/doi.org\/10.1001\/virtualmentor.2012.14.7.oped2-1207.","journal-title":"AMA J Ethics"},{"key":"3068_CR38","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2147\/PPA.S205819","volume":"13","author":"L Bailo","year":"2019","unstructured":"Bailo L, Vergani L, Pravettoni G. Patient preferences as guidance for information framing in a medical shared decision-making approach: the bridge between nudging and patient preferences. Patient Prefer Adherence. 2019;13:2225\u201331. https:\/\/doi.org\/10.2147\/PPA.S205819.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3068_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2478\/jhp-2023-0009","volume":"10","author":"S Fletcher","year":"2023","unstructured":"Fletcher S, Jenner K, Khair K. Shared decision-making forgene therapy in haemophilia care. J Haem Pract. 2023;10(1):62\u20137. https:\/\/doi.org\/10.2478\/jhp-2023-0009.","journal-title":"J Haem Pract"},{"key":"3068_CR40","unstructured":"Pagliarulo N. Bluebird, winding down in Europe, withdraws another rare disease gene therapy. BioPharm Dive. 21 Oct 2021. Accessed 26 Aug 2022. https:\/\/www.biopharmadive.com\/news\/bluebird-withdraw-gene-therapy-europe-skysona\/608666\/."},{"key":"3068_CR41","unstructured":"National Institute for Health and Care Excellence Draft guidance consultation: Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B. National Institute for Health and Care Excellence. 02 Aug 2023. Accessed 06 Aug 2023. https:\/\/www.nice.org.uk\/guidance\/gid-ta10699\/documents\/draft-guidance."},{"key":"3068_CR42","unstructured":"Khair K, Redfren N. Beyond approval: considerations and challenges in access to gene therapy. London: Haemnet; 28 Nov 2022. Accessed 19 Jan 2023. https:\/\/anchor.fm\/haemnet."},{"issue":"3","key":"3068_CR43","doi-asserted-by":"publisher","first-page":"324","DOI":"10.4103\/2249-4863.161306","volume":"4","author":"L Leung","year":"2015","unstructured":"Leung L. Validity, reliability, and generalizability in qualitative research. J Family Med Prim Care. 2015;4(3):324\u20137. https:\/\/doi.org\/10.4103\/2249-4863.161306.","journal-title":"J Family Med Prim Care"},{"issue":"13","key":"3068_CR44","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1177\/1049732318788379","volume":"28","author":"L Carminati","year":"2018","unstructured":"Carminati L. Generalizability in qualitative research: a tale of two traditions. Qual Health Res. 2018;28(13):2094\u2013101. https:\/\/doi.org\/10.1177\/1049732318788379.","journal-title":"Qual Health Res"},{"key":"3068_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2648.2006.03721.x","volume":"53","author":"L Zimmer","year":"2006","unstructured":"Zimmer L. Qualitative meta-synthesis: a question of dialoguing with texts. J Adv Nurs. 2006;53:311\u20138. https:\/\/doi.org\/10.1111\/j.1365-2648.2006.03721.x.","journal-title":"J Adv Nurs"},{"key":"3068_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1365-2648.2009.05250.x","volume":"66","author":"D Finfgeld-Connett","year":"2010","unstructured":"Finfgeld-Connett D. Generalizability and transferability of meta-synthesis research findings. J Adv Nurs. 2010;66:246\u201354. https:\/\/doi.org\/10.1111\/j.1365-2648.2009.05250.x.","journal-title":"J Adv Nurs"},{"key":"3068_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.12.027","author":"L Baas","year":"2023","unstructured":"Baas L, van der Graaf R, van Hoorn ES, Bredenoord AL, Meijer K. for the SYMPHONY consortium. The ethics of gene therapy for hemophilia: a narrative review. J Thromb Haemost. 2023. https:\/\/doi.org\/10.1016\/j.jtha.2022.12.027.","journal-title":"J Thromb Haemost"},{"key":"3068_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1609406919874596","volume":"18","author":"MM Archibald","year":"2019","unstructured":"Archibald MM, Ambagtsheer RC, Casey MG, Lawless M. Using Zoom videoconferencing for qualitative data collection: perceptions and experiences of researchers and participants. Int J Qual Methods. 2019;18:1\u20138. https:\/\/doi.org\/10.1177\/1609406919874596.","journal-title":"Int J Qual Methods"},{"key":"3068_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/1609406920937875","author":"B Lobe","year":"2020","unstructured":"Lobe B, Morgan D, Hoffman KA. Qualitative data collection in an era of social distancing. Int J Qual Methods. 2020. https:\/\/doi.org\/10.1177\/1609406920937875.","journal-title":"Int J Qual Methods"},{"issue":"1","key":"3068_CR50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2478\/jhp-2021-0019","volume":"8","author":"S Fletcher","year":"2021","unstructured":"Fletcher S. Seeing the bigger picture: qualitative research in the Zoom\u00ae age. J Haem Pract. 2021;8(1):141\u20134. https:\/\/doi.org\/10.2478\/jhp-2021-0019.","journal-title":"J Haem Pract"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03068-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03068-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T17:04:34Z","timestamp":1707584674000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03068-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3068"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03068-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each participant was sent a copy of the study PIS detailing the rationale and goals of the study. Written informed consent was then obtained prior to interview and confirmed verbally at the interview. The study was reviewed by the UK Healthcare Research Authority and the Southeast Scotland Research Ethics Committee (20\/SS\/0061), and approval was granted for all study elements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants have consented to their anonymised data being used in any presentation or publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Simon Fletcher, Kate Khair, Kathryn Jenner and Michael Holland are employees of Haemnet Ltd. Simon Fletcher is undertaking a Ph.D. funded by Haemnet Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Exigency Protocol was written with the assistance of a patient representative (a person with haemophilia who has subsequently gone on to have gene therapy). This representative was also involved in the design of the interview schedule. The protocol was also reviewed before REC submission by two patient representatives: a woman with Haemophilia with an affected son, and a partner of a person with haemophilia.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"PPI Statement"}}],"article-number":"59"}}